We have identified and visualized the vasopressin (VP) receptors expressed by hypothalamic magnocellular neurons in supraoptic and paraventricular nuclei. To do this, we used RT-PCR on total RNA extracts from supraoptic nuclei or on single freshly dissociated supraoptic neurons, and in situ hybridization on frontal sections of hypothalamus of Wistar rats.
mRNA is present in vasopressinergic magnocellular neurons.
In light of these results, in situ hybridization was performed to visualize the V 1a and V 1b receptor mRNAs in supraoptic and paraventricular nuclei. Simultaneously, we coupled this approach to: 1) in situ hybridization detection of oxytocin or VP mRNAs; or 2) immunocytochemistry to detect the neuropeptides. This provided a way of identifying the neurons expressing perceptible amounts of V 1a or V 1b receptor mRNAs as vasopressinergic neurons.
Here, we suggest that the autocontrol exerted specifically by VP on vasopressinergic neurons is mediated through, at least, V 1a and V 1b subtype receptors. (Endocrinology 139: 4701-4707, 1998) V ASOPRESSIN (VP) is a neuropeptide synthesized in the magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei. These neurons project themselves toward the neurohypophysis and release VP into the peripheral circulation to regulate plasma volume, osmolarity, and liver glycogenolysis (reviewed in Ref. 1) . In addition, VP serves as a peptidic neurotransmitter in the central nervous system and exerts various functions, such as regulation of body temperature or blood pressure, brain development, and modulation of behavior or memory (1) . VP is thought to generate these various responses by binding to G protein-coupled receptors (1) . To date, three types of VP receptors have been described: V 1a , V 1b , and V 2 , all defined on the basis of the second messenger system to which they are coupled and the affinity profile for various VP agonists and antagonists. The V 1 receptors are coupled to phospholipase C and phosphoinositol hydrolysis (2, 3) . This type of receptor is delineated into the V 1a and V 1b subtypes. The V 1a receptors were detected in the brain, liver, and blood vessels (4 -6) . The V 1b receptors, detected in the anterior pituitary, were involved in the ACTH release (7) . The V 2 receptors were localized in the kidney and are coupled to adenylyl cyclase (8) . The three types of receptors have been cloned and share important homologies (for V 1a receptor: Refs. 9 -12; for V 1b receptor: Refs. 13-15; for V 2 receptor: Refs. 16 -18) .
In the central nervous system, VP has been demonstrated to modulate electrical activities of magnocellular VP neurons (19 -22) caused by a somato-dendritic release of VP in the extracellular space of the paraventricular and supraoptic nuclei (23) (24) (25) . Microspectrofluorimetric studies on dissociated supraoptic neurons confirmed the presence of specific receptors on the cell body of VP neurons (26 -28) . Although the action of VP seems to be predominantly mediated by V 1 -type VP receptors (26 -29) , there is also some electrophysiological (20) and pharmacological (30, 31) (6, (32) (33) (34) (35) (36) . Binding sites or V 1a receptor messenger RNA (mRNA) have been localized in various area of the central nervous system (33, 34, 37, 38) . However, autoradiographic studies have failed to reveal VP-binding sites on the magnocellular neurons of supraoptic and paraventricular nuclei (6, 32, 34, 36) . In situ hybridization has provided a way of detecting the V 1a receptor mRNA only in the parvocellular part of the paraventricular nucleus and in areas just dorsal to the supraoptic nucleus (5) . V 1b receptor transcripts have been detected in several extrapituitary regions, including the hypothalamus (14) ; and V 1b receptor-immunoreactive cell bodies have been observed in the paraventricular and supraoptic nuclei (39) . Furthermore, neuroanatomical data revealed that VP binding sites in the hypothalamic magnocellular nuclei are localized on VP-containing neurons (40) .
Functional evidence of VP receptors in hypothalamic magnocellular nuclei, therefore, has been established. However, the nature of the receptor expressed remains unclear. Therefore, we have identified and visualized the VP receptors expressed by the magnocellular neurons of supraoptic and paraventricular nuclei of the hypothalamus. Using the very sensitive RT-nested PCR technique, we showed that V 1a predominantly and V 1b (but not V 2 ) receptor transcripts are detectable in dissected supraoptic nuclei of rats from birth to adulthood. RT-PCR, performed at the single-cell level, then showed the presence of V 1a receptor mRNA in both VP and oxytocin (OT) neurons. Finally, using simultaneous in situ hybridization and immunocytochemistry or double in situ hybridization, we were able to show, for the first time, that V 1a and V 1b receptor genes are transcribed in perceptible amounts essentially in the vasopressinergic magnocellular neurons of supraoptic and paraventricular nuclei. Wistar rats were used in accordance with the European laws for the care and use of experimental animals.
Materials and Methods Materials

RT-PCR.
Wistar rats (0-, 6-, 10-, 14-, 21-, 28-day-old, and adult) were decapitated, and the supraoptic nuclei were rapidly microdissected, frozen in liquid nitrogen, pooled by 10 animals (half male, half female), and stored at Ϫ80 C until processed.
Single-cell RT-PCR. Magnocellular neurons, freshly dissociated from supraoptic nuclei of 1-month-old female rats, were prepared using a combined enzymatic and mechanical cell dissociation procedure (41) . The cytoplasm from individual cells was collected by suction using a glass micropipette, blown in an Eppendorf microtube, immediately frozen in liquid nitrogen, and kept at Ϫ80 C until processed.
In situ hybridization. One-month-old male Wistar rats were decapitated, and their brains were rapidly removed, frozen at Ϫ50 C in isopentane, and stored at Ϫ80 C until processed. Sections of 12 m were cut at Ϫ20 C with a Leica Corp. CM3000 cryostat, thaw-mounted on polylysinetreated slides, and processed for hybridization.
Primers for RT-PCR and probes for in situ hybridization
The primers for RT and nested PCR, and the probes for in situ hybridization (Table 1) , were chosen on the rat V 1a , V 1b , and V 2 VP receptor mRNA sequences using CPrimer 1.09 (G. Bristol and R. D. Andersen, University of California, Los Angeles, CA) and Amplify 1.2 (W. Engels, University of Wisconsin, Madison, WI) softwares. The specificity of the sequences chosen for each subtype of VP receptor, as well as the absence of cross-reaction with the OT receptor mRNA, were carefully verified. The BLAST software (National Center for Biotechnology Information, Bethesda, MD), set at its maximal sensitivity, was also used to check that the primers and probes did not match significantly any other known RNA or DNA sequence. To improve the sensitivity of detection by in situ hybridization, two probes were selected for each receptor subtype. For the PCR study, an intron lies between the forward and reverse primer sets chosen for the three types of receptors studied (formally for the V 2 receptor whose rat genomic DNA sequence is known; by analogy with the human and sheep genomic sequences for the V 1a receptor; by analogy with the V 1a , V 2 , and OT receptors for the V 1b receptor whose genomic sequence has not yet been released in the gene databases, for any species). Because of the use of the very sensitive nested-PCR procedure, this ensures rejection (on the basis of the size) of PCR bands amplified on any contaminating genomic DNA that could have resisted to the DNA digestion before the RT step. Controls, by omitting the RT step, were also performed.
RT and PCR
The total RNA of the supraoptic nuclei was extracted using the RNeasy kit (Qiagen, Courtaboeuf, France). The RT was performed on the RNA extract previously digested with deoxyribonuclease (DNAse) I (Life Technologies, Cergy Pontoise, France), using Superscript II reverse transcriptase (Life Technologies) according to the manufacturer's instructions, RNasin (Promega Corp., Charbonnières, France) as a RNase inhibitor, and the R1 reverse primer ( Table 1 ).
The DNA amplification was then performed using PTC-100/60 or PTC-150/16 thermal controllers (MJ Research, Inc., Watertown, MA), Taq DNA Polymerase (Life Technologies) according to the manufacturer's instructions, and the primer sets described in Table 1 . The first PCR was made using the F1 forward primer and the R1 reverse primer previously used for RT. The nested PCR was performed using the F2 forward primer and the R2 reverse primer. Settings are provided in Table 1 .
The PCR products were electrophoresed on a 2% agarose gel in TAE buffer (40 mm Tris-acetate, 1 mm EDTA, pH 8) containing 0.5 g/ml ethidium bromide, observed under UV light, and photographed. The lengths of the PCR products were as expected ( Table 1) . Specificity of the DNA bands obtained after amplification was also verified by digesting the PCR products with appropriate restriction enzymes; the lengths of the main fragments were as expected (Table 1) .
Single-cell PCR
The RT was performed directly on the cytoplasm (without RNA extraction) using simultaneously three R1 reverse primers: one for copying both VP and OT transcripts, one for the V 1a , and one for the V 1b VP receptor transcripts (Table 1) . A first-nested PCR provided a way of identifying the magnocellular neuron as a VP or OT neuron. A secondnested PCR, consuming the rest of the RT product, was performed to detect either the V 1a or V 1b receptor transcript. Four VP and four OT neurons were studied for each receptor subtype.
Combined in situ hybridization and immunocytochemistry
The receptor probes were 3Ј end-labeled with biotin 16-deoxyuridine 5-triphosphate using terminal transferase (Boehringer Mannheim). The sections were air-dried and fixed in 4% paraformaldehyde in 0.1 m phosphate buffer for 20 min at room temperature. After washing with PBS (130 mm NaCl, 7 mm Na 2 HPO 4 , 3 mm NaH 2 PO 4 ), the sections were dehydrated in increasing concentrations of ethanol (70% and 95%) and air dried. The sections were then flooded with the two specific probes dissolved at 10 nm final concentration in hybridization buffer (50% deionized formamide, 0.08 m Tris buffer (pH 7.5), 0.6 m NaCl, 4 mm EDTA, 0.05% Na 2 H 2 P 2 O 7 , 0.05% Na 4 P 2 O 7 , 0.2% N-lauroylsarcosine). The hybridization was performed in a humid chamber overnight at 42 C. After incubation, the slides were washed, at 45 C, in decreasing concentrations of saline-sodium citrate (2ϫ, 0.5ϫ and 0.1ϫ for 30 min each; 1ϫ saline-sodium citrate is 150 mm NaCl, 15 mm sodium citrate, pH 7).
When in situ hybridization was combined with immunocytochemistry, the unrevealed hybridized sections were incubated overnight with the polyclonal rabbit anti-VP antibody (diluted to 1/400 in 1ϫ PBS, 2% BSA, 0.1% N-lauroylsarcosine) or with the mouse anti-OT neurophysin PS38 monoclonal antibody (diluted to 1/200 in 1ϫ PBS, 2% BSA, 0.1% N-lauroylsarcosine). The sections were then incubated for 1 h, simultaneously with Cy3-streptavidin (Sigma Chemical Co.) to reveal the oligonucleotidic probes, and either with oregon green-conjugated antirabbit antibody or oregon green-conjugated antimouse antibody (diluted to 1/200 in 1ϫ PBS, 2% BSA) to reveal the peptide.
When detections of receptor and peptide mRNAs were combined (double in situ hybridization), the probes for OT or VP mRNA were 3Ј end-labeled with digoxigenin 11-deoxyuridine 5-triphosphate. After posthybridization washings, the sections were treated for 15 min with 1% H 2 O 2 in 1ϫ PBS to inactivate endogenous peroxidase. To detect combined V 1a and V 1b receptor mRNAs, the probes for V 1a receptor mRNA (labeled with biotin) and those for V 1b receptor mRNA (labeled with digoxigenin) were hybridized simultaneously (42) . The V 1a receptor mRNA was then revealed using the tyramide signal amplification system (Cy3-tyramide). After inactivation of resting peroxidase activity with 0.01 n HCl for 10 min at room temperature, V 1b receptor mRNA was revealed by incubation for 1 h with sheep horseradishperoxidase-conjugated antidigoxigenin Fab fragments (Boehringer; 1/100 in 0.1 m Tris buffer, 0.15 m NaCl, 0.5% blocking reagent) followed by amplification with fluorescein-tyramide (42) .
The sections were then washed with 0.1 m Tris buffer, 0.15 m NaCl, 0.05% Tween 20, mounted in Mowiol, and observed with a Leica Corp. TCS 4D confocal microscope. Images were processed using Adobe Photoshop 3.0 (San Jose, CA).
The controls were: 1) use of unlabeled probes or omission of probes; 2) competition between an excess of unlabeled probes and labeled probes in the hybridization reaction; and 3) omission of different molecules involved in biotin or digoxigenin detection. All the controls returned the hybridization signals to background levels. For the V 1a and V 1b receptor mRNAs double hybridization, the complete inactivation of peroxidase rest activity between the two tyramide deposit reactions was essential because omission of this step could have lead to repeated deposit of the second tyramide in the vicinity of the mRNA target detected first. The 0.01 n HCl inactivation procedure (42) , which appeared to affect neither the first fluorescent in situ elongation: 72 C, 90 sec P: 2534 -2566 F and R, forward and reverse primers for PCR, respectively. 1, First PCR; 2, nested PCR; P, probe for in situ hybridization. a The presence of an intron between the two primers used for PCR. ID, identification.
hybridization signal nor the cell morphology, was checked as efficient, because a second round of amplification with fluorescein isothiocyanatetyramide, after this treatment, did not add the fluorescein isothiocyanatesignal in the vicinity of the previous Cy3-signal.
Results
V 1 VP receptors are expressed from birth in the supraoptic nucleus
RT was performed on total RNA extracts from supraoptic nuclei (whose contaminating genomic DNA was previously digested with DNAse I) using simultaneously the three R1 primers specific for V 1a , V 1b , and V 2 receptors (Table 1) . Then, PCR performed separately with the three F1 and R1 primer sets designed to detect VP receptors (Table 1) revealed that the V 1a subtype is expressed from birth to adulthood in this brain area (Fig. 1A) . The V 1b and V 2 receptor transcripts were undetectable at all the ages studied.
To increase the detection sensitivity for V 1b and V 2 receptor mRNAs, a second PCR was performed on the products from the first PCR using the F2 and R2 nested primer sets (Table 1 ). This nested amplification provided a way of detecting V 1b receptor transcripts at all the ages studied (Fig.  1B) . Conversely, nested PCR failed to detect V 2 receptor transcripts in the RNA extracts from supraoptic nuclei at all the ages studied, even under very high amplification conditions (as a control, it was verified that the primer set can detect V 2 transcripts in kidney extracts). Consequently, the V 1a subtype is the major VP receptor detected in the supraoptic nucleus, whereas V 1b is a minor isoform.
Both VP and OT magnocellular neurons express the V 1a receptor
The cytoplasm from the single freshly dissociated neurons was used as substrate for simultaneous search for transcripts of VP, OT, and either V 1a or V 1b receptor genes. The RTnested PCR revealed that the V 1a receptor mRNA is present in the neurons that produce the prepro-VP mRNA, as well as in those that produce the prepro-OT mRNA (Fig. 2) . At the single-cell level, the mRNA for V 1b receptor remained undetectable (not shown).
V 1a and V 1b receptors are mostly expressed in vasopressinergic neurons
Based on RT-PCR results, in situ hybridization was performed to visualize the V 1a and V 1b receptor transcripts on frontal sections of rat hypothalamus. For each VP receptor mRNA subtype, two specific oligonucleotidic biotinylated probes (P1 and P2, Table 1 ) were hybridized simultaneously and revealed using the tyramide signal amplification system. They provided a way of visualizing V 1a and V 1b receptor mRNAs in magnocellular neurons of both supraoptic (Fig. 3 ) and paraventricular nuclei (not shown). The signal for both VP receptor mRNAs was detected all over the cell body, generally with patches of intense fluorescence distributed in the cell body ( Fig. 3 ; G, J, M, P, and S-U). The punctate labeling may arise from the combination of: observation on a confocal microscope (about 1-m depth), low level of The frontal sections of the supraoptic nucleus of male rats were submitted to in situ hybridization to visualize the V 1a receptor mRNA (A, D, G, J, and S) and the V 1b receptor mRNA (M, P, and T), and either to immunocytochemistry (B and E) or in situ hybridization (H, K, N and Q) to identify the peptide present in magnocellular neurons. The superimposed images (C, F, I, L, O, and R) clearly showed that V 1a receptor transcripts are produced in vasopressinergic neurons (A-C) or in VP mRNA containing neurons (G-I; note one cell expressing V 1a receptor mRNA but not VP mRNA, arrowheads) but not in oxytocinergic neurons (D-F) or in OT mRNA containing neurons (J-L). In the same way, the neurons expressing VP mRNA also produced V 1b receptor mRNA (M-O; note two cells expressing V 1b receptor mRNA but not VP mRNA, arrowheads). The neurons expressing OT mRNA did not produce the V 1b receptor mRNA (P-R). The images J-L and P-R show that the V 1a (J) or the V 1b (P) receptor mRNA was hardly detectable in dorsal and anterior parts of the supraoptic nucleus, where OT mRNA-containing neurons (K, Q) were concentrated. The images S-U show that the V 1a and V 1b receptor mRNAs are expressed by the same magnocellular neurons. Bar, 20 m in A for A-F, in G for G-U; AVP, arginine VP. mRNAs nonuniformly distributed, and finally, use of an efficient amplification procedure.
In situ hybridization was coupled to immunocytochemical identification of OT or VP peptides. Neurons exhibiting V 1a receptor mRNA were immunoreactive to VP (Fig. 3, A-C) and not to OT (Fig. 3, D-F) . The colocalization of V 1a receptor mRNA and VP was attested by the fact that all neurons were yellow-colored when the two images of in situ hybridization (Fig. 3A: red fluorescence for V 1a receptor mRNA) and immunocytochemistry (Fig. 3B: green fluorescence for VP) were superimposed (Fig. 3C) . In contrast, the yellow color never appeared when the in situ hybridization image of V 1a (Fig.  3D ) and the immunocytochemistry image of OT (Fig. 3E) were superimposed (Fig. 3F) .
To confirm the identification of the neurons expressing VP receptors, a double in situ hybridization was performed. One oligonucleotidic digoxigenin-labeled probe, specific for either OT or VP mRNA (P, Table 1 ), was hybridized simultaneously with the two biotinylated probes designed to detect each VP receptor mRNA subtype (P1 and P2, Table 1 ). The double labeling showed that the magnocellular neurons exhibiting either V 1a or V 1b receptor mRNAs also express mRNA for VP (Fig. 3 , G-I and M-O). In the absence of VP signal, a few cells displayed a V 1a or V 1b signal (Fig. 3 , G-I for V 1a , arrowheads; M-O for V 1b ). Conversely, with few exceptions, the OT mRNA did not colocalize with V 1a or V 1b receptor mRNA (Fig. 3 , J-L and P-R): only 3-4 cells coexpressing OT mRNA and V 1a or V 1b receptor mRNAs were observed during the course of our investigation (not shown). In fact, V 1a and V 1b receptor mRNAs were not easily detectable in the dorsal and anterior parts of the supraoptic nucleus, the region where OT neurons are mainly concentrated. In more median areas of the supraoptic nucleus, some neurons exhibiting OT mRNA were closely mixed with many other neurons exhibiting V 1a or V 1b receptor mRNAs (Fig. 3 , J-L and P-R). The rare cells coexpressing OT mRNA and V 1a or V 1b receptor mRNA were observed in these regions.
The double in situ hybridization, to detect V 1a and V 1b receptor mRNAs revealed sequentially by the tyramide signal amplification system, showed that the V 1a and V 1b receptor mRNAs are colocalized in the same neurons, with, however, varying signal intensity within the cell (which ruled out the possibility of a cross-reaction between the two sequential amplifications) (Fig. 3, S-U) .
Discussion
The RT-PCR showed the continuous presence of V 1a and V 1b receptor mRNAs in rat supraoptic nucleus from birth to adulthood. Conversely, the presence of V 2 receptor transcripts in this brain area was ruled out: the amplification was carried out, far enough to sometimes detect, in the RNA extracts, the rare contaminating genomic DNA molecules having escaped the digestion by DNAse I, without giving any signal corresponding to the V 2 receptor mRNA. Clearly, the electrophysiological (20) and pharmacological (30, 31) evidence of V 2 -like responses in the supraoptic nucleus might be explained by other mechanisms than the presence of a V 2 -type receptor. Taken together, the neurons of the supraoptic nucleus transcribe the VP receptors of the V 1a and V 1b subtypes, the V 1a seeming to be the major isoform, as evidenced by the PCR results. The presence of V 1a receptor mRNA in VP neurons was confirmed by single-cell RT-PCR. Unfortunately, the same procedure was insufficiently sensitive to detect V 1b receptors.
Using in situ hybridization with an antisense riboprobe, Ostrowski et al. (4, 5) found no V 1 receptor transcripts in the supraoptic nucleus and the magnocellular part of paraventricular nucleus. However, V 1b receptor protein was detected in this area by immunocytochemistry (39) . To improve the detection sensitivity of in situ hybridization, we used simultaneously two oligonucleotidic probes for each receptor mRNA, a procedure recently introduced by Trembleau and Bloom (43) . We also used biotin labeling of the probes and detection of the hybrids, by the very efficient tyramide signal amplification, to reveal the hybridized molecules. The result of these methodological choices was the visualization (for the first time, to our knowledge) of V 1a and V 1b receptor transcripts in the magnocellular neurons of supraoptic and paraventricular nuclei.
Furthermore, using either double in situ hybridization or a combination of in situ hybridization with immunocytochemistry, we clearly show that the great majority of the magnocellular neurons displaying the V 1a and V 1b receptor signals are those that synthesize VP. A few exceptions may probably concern the magnocellular neurons that contain both VP and OT (27, 44 -46) . They may also comprise the very small proportion of magnocellular neurons (up to 0.1%) where a crossing-over occurs between the close VP and OT genes, leading to hybrid VP and OT mRNAs (47, 48) .
The present results surprisingly showed that V 1a receptor mRNA was detectable by single-cell RT-PCR in the magnocellular OT neurons. Nevertheless, they also showed that the amount of this mRNA is probably very low, because it is undetectable using highly sensitive in situ hybridization. However, the physiological relevance of the V 1a receptor mRNA in oxytocinergic neurons remains to be determined, especially because these neurons do not respond to VP or V 1 agonists, neither in vivo nor as freshly dissociated cells (22, 27) . The presence of V 1a receptor mRNA suggests that VP may act directly on OT neurons via this receptor, rather than at high concentrations via the OT receptor. Another possibility is that OT neurons possess the intrinsic potentiality to respond directly to VP under particular physiological demands. This dual potentiality could be expressed, for example, during parturition or lactation, when the percent of cells expressing both VP and OT mRNAs increases markedly (49, 50) .
Taken together, our experimental data show that the magnocellular VP neurons of the supraoptic and paraventricular nuclei express simultaneously the V 1a and V 1b VP receptors. VP modulates the electrical activity of VP neurons by exerting either inhibitory or excitatory effects (19 -21, 31) . This modulation leads the population of VP neurons to discharge with an optimized specific phasic pattern (22) , the most efficient for systemic hormone release. The complexity of the autocontrol exerted by VP on VP neurons may arise, in part, from the interplay between V 1a and V 1b receptors.
